Esophageal Cancer Awareness Month: Tislelizumab Approval & Future Research

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Learn more about the latest advancements in esophageal cancer treatment here: https://oncdata.com/esophageal-cancer-awareness-month-harry-yoon

0:00 Introduction
1:00 Esophageal Squamous Cell Carcinoma
1:25 Tislelizumab
1:36 RATIONALE-306 trial
2:42 Tislelizumab Approval
4:55 Adverse Event Management
5:10 Other Advances in Esophageal Cancer
7:20 Esophageal Cancer Awareness Month

April is Esophageal Cancer Awareness Month, a time to spotlight one of the most aggressive cancers worldwide. In this interview, Dr. Harry Yoon, Professor of Oncology at the Mayo Clinic and lead investigator of the RATIONALE-306 trial, discusses the recent FDA approval of tislelizumab as a first-line treatment for unresectable or metastatic esophageal squamous cell carcinoma (ESCC).

Dr. Yoon shares insights into the trial’s findings, which demonstrated significant survival benefits with tislelizumab, and highlights its unique role in combination with a taxane doublet. He also explores future directions in ESCC research, including immune checkpoint inhibitors, antibody-drug conjugates, and angiogenesis inhibitors.

Join us in raising awareness about esophageal cancer and the importance of continued research to improve outcomes for patients with this challenging disease.

#EsophagealCancer #CancerAwareness #Tislelizumab #FDAApproval #ESCC #Immunotherapy #OncologyResearch #CancerTreatment #EsophagealCancerAwarenessMonth #OncologyCare
Category
Oncology
Be the first to comment

Up Next